Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape
CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC
Solange Peters, Switzerland: CheckMate 227 Part 1 final analysis
CheckMate-227: Nivolumab + Ipilimumab in mNSCLC
Three-Year Update From the CheckMate 227 Clinical Trial for Advanced NSCLC
Nivolumab + Ipilimumab + 2 Cycles of Platinum-doublet Chemo vs 4 Cycles Chemo for Stage IV NSCLC
Dual Checkpoint Inhibition in NSCLC: CheckMate-227
Researcher comment: Take-home messages from the CheckMate 227 trial | Solange Peters
Results from CheckMate-227 : Immune combination reaches PFS endpoint
David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Front Line Therapy
CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC
Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer
Are TMB and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Nivo/Ipi Rx of Choice for Adv. NSCLC, PD-L1 Under 1%, High TMB? New CheckMate 227 Data (BMIC-040)
Long-Term Survival with Nivolumab + Ipilimumab in Advanced NSCLC | Dr. Sandeep Ishi | CRSF 2023
Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Drive...
Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents
The role of Immunotherapy in stage IV NSCLC (PDL1 high/low)Dr. Julian Molina Day 2
Deep Insight Into Immuno-Oncology: Immunotherapy Pathways, Targets, and Biomarkers